An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs MIV 711 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Medivir AB
- 04 Apr 2018 According to a Medivir AB media release, company expects to complete this trial in 2018.
- 27 Dec 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 According to a Medivir AB media release, the independent Data Monitoring Committee (DMC) has again recommended continuation of the extension study without modifications, based on the planned final review of the accumulated safety data.